Respiratory Medicine
Volume 104, Issue 10 , Pages 1460-1472 , October 2010

A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients

  • E.D. Bateman

      Affiliations

    • Division of Pulmonology, Department of Medicine, University of Cape Town, George Street, Mowbray, Cape Town 7700, South Africa
    • Corresponding Author InformationCorresponding author. Tel.: +27 21 406 6901; fax: +27 21 406 6902.
    • ,
  • D. Tashkin

      Affiliations

    • Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Los Angeles, CA 90095-1690, USA
    • ,
  • N. Siafakas

      Affiliations

    • University of Crete, University General Hospital, Department of Thoracic Medicine, 7110 Heraklion, Greece
    • ,
  • R. Dahl

      Affiliations

    • Department of Respiratory Diseases, Aarhus University Hospital, Norrebrogade, DK 8000 Aarhus C, Denmark
    • ,
  • L. Towse

      Affiliations

    • Clinical Research Department, Medical Division, Boehringer Ingelheim Limited, Ellesfield Avenue, Berkshire RG12 8YS, Bracknell, UK
    • ,
  • D. Massey

      Affiliations

    • Clinical Research Department, Medical Division, Boehringer Ingelheim Limited, Ellesfield Avenue, Berkshire RG12 8YS, Bracknell, UK
    • ,
  • D. Pavia

      Affiliations

    • Clinical Research Department, Medical Division, Boehringer Ingelheim Limited, Ellesfield Avenue, Berkshire RG12 8YS, Bracknell, UK
    • ,
  • N.S. Zhong

      Affiliations

    • State Key Laboratory of Respiratory Disease/Guangzhou Institute of Respiratory Disease, Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, China

Received 18 January 2010 ,Accepted 4 June 2010.

References 

  1. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J. 2002;19:209–216
  2. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217–224
  3. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399–404
  4. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003;124:1743–1748
  5. O’Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840
  6. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317–326
  7. Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl. 1):S19–S24
  8. Hochrainer D, Holz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist Inhaler™ and pressurized metered dose inhalers. J Aerosol Med. 2005;18:273–282
  9. Newman SP. Use of gamma scintigraphy to evaluate the performance of new inhalers. J Aerosol Med. 1999;12(Suppl. 1):S25–S31
  10. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ Inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18:264–272
  11. Bateman E, Singh D, Smith D, Disse B, Towse L, Massey D, et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomised studies. Int J COPD. 2010;5:197–208
  12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardisation of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J. 1993;6(Suppl. 16):5–40
  13. Jones PW. St George’s respiratory questionnaire: MCID. COPD. 2005;2:75–79
  14. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554
  15. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–222
  16. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511–1520
  17. van Noord JA, Aumann J-L, Janssens E, Smeets JJ, Zaagsma J, Mueller A, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104:995–1004
  18. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695–1703
  19. Singh S, Loke YK, Furberg CD. Adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439–1450
  20. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006;61:854–862
  21. Rodrigo GJ, Castro-Rodriguez JA, Nannini LJ, Plaza Moral V, Schiavi EA. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir Med. 2009;103(10):1421–1429
  22. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397–409
  23. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest. 2004;125:2309–2321
  24. van Noord JA, Cornelissen PJG, Aumann J-L, Platz J, Mueller A, Fogarty C. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir Med. 2009;103:22–29
  25. Schürmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat® Soft Mist™ inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4:53–61
  26. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat® Soft Mist™ Inhaler. Int J COPD. 2009;4:381–390

PII: S0954-6111(10)00283-0

doi: 10.1016/j.rmed.2010.06.004

Respiratory Medicine
Volume 104, Issue 10 , Pages 1460-1472 , October 2010

Article Tools

* Image Usage & Resolution